TP53

Aptose Reports Results for the First Quarter 2023

Retrieved on: 
Lunedì, Maggio 8, 2023
TP53, APS, CRH, NPM1, Aes, Food and Drug Administration, Clinical trial, G1, Absorption, Aplastic anemia, Trial of the century, Acute myeloid leukemia, Phase 1, AML, Running, Drug-related deaths in the United Kingdom, MLL, Patient, RAS, SAN, EHA, RUNX1, IDH, FLT3, TSX, CRi, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, FDA, CRP, Gene, Safety, Pharmaceutical industry, DNMT3A, G3

─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;

Key Points: 
  • ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;
    SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for first quarter ended March 31, 2023, and provided a corporate update.
  • “While it is still too early to report confirmed responses in the APTIVATE trial, it is moving in the right direction.
  • Aptose has identified a safe therapeutic range with a broad therapeutic window, spanning the dose levels of 40, 80, 120 and 160 milligrams.
  • If findings continue as anticipated, Aptose plans to escalate the dose of G3 and seek a dose with robust safety and higher exposure levels.

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
Mercoledì, Aprile 26, 2023
Therapy, TP53, HLA, Neoplasm, Monroe Dunaway Anderson, MD Anderson Cancer Center, TCR, ASCO, Assistant professor, American Society of Clinical Oncology, Patient, Division, EGFR, University, Annual general meeting, Society, Medical imaging

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

Key Points: 
  • HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.
  • The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation trial being conducted at The University of Texas MD Anderson Cancer Center.
  • The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers that have a matching human leukocyte antigen (HLA) whose tumors contain at least one of the targeted driver mutations in KRAS, TP53 and EGFR.
  • Details of the poster presentation are as follows:
    Presenter: Maria Pia Morelli, M.D., Ph.D., Assistant Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at MD Anderson
    For more information, visit the ASCO Annual Meeting website.

Bionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research

Retrieved on: 
Mercoledì, Aprile 26, 2023
CLL, Myelodysplastic syndrome, FISH, University, CDK6, TP53, Chronic lymphocytic leukemia, ALL, Acute lymphoblastic leukemia, Genomics, Bone marrow, SVS, KMT2A, Doctor of Philosophy, VAF, SV, Teaching hospital, Acute myeloid leukemia, Ruhr University Bochum, MDS, AML, Publication, SAN, In situ hybridization, Cytogenetics, OGM, University of Oulu, Vaccine, Microscope, TCL1A

The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.

Key Points: 
  • The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.
  • The authors also noted OGM’s ability to detect currently unknown variants, which might give insight into disease biology and refine risk stratification.
  • evaluated the performance of OGM against traditional cytogenetic methods in 29 samples characterized as AML or ALL.
  • is one of the first studies to evaluate the utility of OGM in chronic lymphocytic leukemia (CLL) samples.

Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs

Retrieved on: 
Martedì, Aprile 18, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AACR, Perforin-1, PD, TP53, TGF, Neoplasm, ATF3, Cancer, Toxicity, SOC, Biomarker, Messenger, AML, Protein, Patient, Standard of care, Risk, T-cell surface glycoprotein CD3 epsilon chain, Growth, DDIT3, PD-1, FDA, Pembrolizumab, Therapy, GSPT1, Breast cancer, Vaccine, Palladium, Pharmaceutical industry, Regulatory T cell, CBL (gene)

The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • “We are also excited to unveil at AACR our new TPS² platform, which has the potential to achieve the full promise of Cbl-b inhibitors through T cell-specific delivery.
  • Orum identified the depletion of GSPT1 as a target-proximal pharmacodynamic biomarker in ORM-5029 treated in vitro and in vivo samples.
  • PD responses correlate with degree and duration of response in an in vivo model treated with ORM-5029.

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Retrieved on: 
Giovedì, Aprile 13, 2023
CLL, NRAS, KRAS, MYC, AACR, Molecule, TP53, Chronic lymphocytic leukemia, Menin, ITD, Acute leukemia, American Association for Cancer Research, MEK, Doctor of Philosophy, BTK, Gene expression profiling, MEN1, NOTCH1, AML, BCL2, Patient, DSM-IV codes, Proteasome inhibitor, Cancer, Acute myeloid leukemia, Growth, Leukemia, Therapy, Gene, Disease, Pharmaceutical industry, Vaccine, Biology, FLT3

Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.

Key Points: 
  • Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.
  • Menin is an epigenetic protein that drives oncogenic function through transcriptional regulation directed by its interactions with various protein partners.
  • Additionally, we show benefit of combinatorial approaches of menin and FLT3 covalent inhibitors with MEK and BCL2 blockade.
  • These data provide initial pre-clinical evidence for combining pathway specific inhibitors as a promising therapeutic strategy for further investigation in acute leukemia.

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Retrieved on: 
Lunedì, Aprile 3, 2023
CLL, ROR1, Aggressive lymphoma, CD19, TP53, Clinical trial, Lung cancer, Cell, N, BTK, PFS, CAR, Patient, Investment, SAN, Bone marrow, MCL, Therapy, IND, LBD, AR, Safety, Prostate cancer, Pharmaceutical industry

The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025.

Key Points: 
  • The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025.
  • The projected cash runway will support the clinical advancement of our two pipeline assets ONCT-808 and ONCT-534.
  • “The dramatic adoption of recently approved Bruton’s tyrosine kinase inhibitors made the continued development of zilovertamab with ibrutinib an unviable commercial opportunity.
  • We estimate that our cash, cash equivalents and short-term investments were $54.3 million, and we had 58.7 million shares of common stock outstanding, as of March 31, 2023, and we expect our cash, cash equivalents and short-term investments to support our planned operations into 2025.

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Giovedì, Marzo 23, 2023
ASH, Lux, APS, Controller, ITD, TKD, G1, BCR, Associate, Accounting, Plasma, RAS, Investment, Patient, RUNX1, Clinical, LYN, TP53, DNMT3A, SYK, European Hematology Association, Research, Aplastic anemia, MRD, BCL2, PLOS One, MLL, Data, FLT3, TSX, Amylin Pharmaceuticals, FDA, Combination, RSK, Lymphoid leukemia, Absorption, BTK, Acute myeloid leukemia, Phase 1, CR, Hand, MD Anderson Cancer Center, Inflammation, Lymphoma, Phosphorylation, National university, NPM1, Clinical trial, European School, Data monitoring committee, AML, BID, EHA, ISTA Pharmaceuticals, Harvard Business School, Toxic leukoencephalopathy, G3, Gene, Society, Pharmaceutical industry, Cryptocurrency, Vaccine, Running

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  • Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million.
  • Aptose Appoints VP, Controller – During the fourth quarter, Aptose appointed Brooks Ensign, Vice President and Controller.
  • A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

Retrieved on: 
Giovedì, Marzo 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Multimedia, Research, Cancer, Blood, DNA, Nucleic acid thermodynamics, University Medical Center, Trial of the century, Partnership, Nanopore sequencing, TP53, Methylation, Patient, University Medical Center Utrecht, TP53-inducible glycolysis and apoptosis regulator, Oxford Nanopore Technologies, Circulating tumor DNA, Otorhinolaryngology, Erasmus MC, Genomics, Medical imaging, Neoplasm, Cyclomancy

CyclomicsSeq can also be used on any Oxford Nanopore device, therefore no new equipment is necessary to perform highly accurate analyses.

Key Points: 
  • CyclomicsSeq can also be used on any Oxford Nanopore device, therefore no new equipment is necessary to perform highly accurate analyses.
  • “We are excited to partner with Cyclomics to increase access to accurate and fast detection of cancer using nanopore sequencing.
  • The CyclomicsSeq technology enables highly accurate sequencing of single cancer DNA molecules in the blood stream of any cancer patient.
  • In the last year we have worked hard to integrate CyclomicsSeq with nanopore sequencing workflows as part of our partnership with Oxford Nanopore Technologies.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Giovedì, Marzo 9, 2023
ORR, Trial of the century, IND, MCL, CLL, Survival, Mutation, Therapy, Mantle cell lymphoma, Ibrutinib, SAN, Patient, PFS, FDA, Investigational New Drug, Cancer, Research, ASH, TP53, Exercise, Investment, Bone marrow, Society, IRB, Vaccine, Pharmaceutical industry

Our total operating expenses for the fourth quarter ended December 31, 2022 were $12.1 million, including $1.8 million in non-cash stock-based compensation expense.

Key Points: 
  • Our total operating expenses for the fourth quarter ended December 31, 2022 were $12.1 million, including $1.8 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $8.8 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • Net loss for the fourth quarter was $11.4 million, or a loss of $0.20 per share, basic and diluted.
  • We believe these funds will be sufficient to fund our operations into the first quarter of 2024.

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Martedì, Marzo 7, 2023
IND, PD-1, TCR, Blood, Development, Public expenditure, TP53, SITC, State Administrative Expenses, FDA, Poster, Therapy, Quarter, Safety, Memory, Telephone, Administration, Environment, Research, Tumor microenvironment, ID, Research and development, EGFR, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, KRAS, MD Anderson Cancer Center, Food, Monroe Dunaway Anderson, Vaccine, Pharmaceutical industry, Cryptocurrency

ET

Key Points: 
  • ET
    HOUSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
  • In the fourth quarter of 2022, the Company successfully dosed its third patient in the trial.
  • In the fourth quarter of 2022 IND amendment, the manufacturing process was enhanced to move from fresh to cryopreserved cell product.
  • Fourth Quarter Ended December 31, 2022 Financial Results
    Research and Development Expenses: Research and development expenses were $5.6 million for the fourth quarter of 2022, compared to $8.2 million for the fourth quarter of 2021, a decrease of approximately 32%.